Evidence map›Paper›PMID 37655300›Full record

ArticleFrontiers in cellular and infection microbiology2023

Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against

Shan Gao, Wenjuan Nie, Lina Liu, Lei Su, Yingxia You, Ruixue Geng, Naihui Chu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Shan GaoTuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Wenjuan NieTuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Lina LiuTuberculosis Department, Hengshui Third People's Hospital, Hengshui, China.
Lei SuTuberculosis Department, Henan Province Anyang City Tuberculosis Prevention and Control Institute, Anyang, China.
Yingxia YouTuberculosis Department, Zhengzhou Sixth People's Hospital, Zhengzhou, China.
Ruixue GengTuberculosis Department, Hohhot Second Hospital, Hohhot, China.
Naihui ChuTuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Beijing Chest Hospital · CNCapital Medical University · CNHeilongjiang Center for Tuberculosis Control and Prevention · CNHengshui University · CNHohhot First Hospital · CNThe Sixth People's Hospital of Zhengzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate contezolid (MRX-I) antibacterial activity against Methods: MRX-I inhibitory activity against Results: MRX-I anti- Conclusion: MRX-I effectively inhibited

Indexed as

Anti-Bacterial AgentsMycobacterium abscessusMycobacterium Infections, NontuberculousOxazolidinonesAnimalsAzithromycinDisease Models, AnimalLinezolidMicrobial Sensitivity TestsSurvival AnalysisZebrafishAnti-Bacterial AgentsAzithromycinLinezolidOxazolidinonesactivitycontezolidin vivoMycobacterium abscessuszebrafish

Identifiers

PMID37655300
PMCPMC10465794
OpenAlexW4385953235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.